A Phase 1 Trial of JMT108 in Adults with Advanced Solid Tumors
Phase 1
270
about 3.8 years
18+
3 sites in NC, TX, VA
About this study
Researchers are testing a new drug called JMT108, which is an antibody treatment, to see if it's safe and effective for adults who have advanced solid tumors. The trial will involve giving JMT108 through intravenous injection every two weeks until the doctor decides that stopping treatment is best. Participants will be followed up regularly to monitor their response to the drug.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take JMT108
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants with Dose Limiting Toxicities as assessed by NCI CTCAE v5.0 (excluding cytokine release syndrome, CRS).
Secondary: JMT 108 Pharmacokinetics: Clearance (CL), JMT108 Objective response rate (ORR), JMT108 Pharmacokinetics: Area under the concentration time curve over the dosing interval, JMT108 Pharmacokinetics: Elimination half-life (t1/2)
Oncology